William J. Sandborn, M. D. , Christopher Gasink, M. D

Slides:



Advertisements
Similar presentations
P. S. KUNDHAL ET AL. JAMA November, 2013 Moderator – Dr Vineet Ahuja
Advertisements

Methotrexate Indications and Approaches
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Emerging treatments in Crohn’s disease and ulcerative colitis
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
Vedolizumab in Pediatric IBD: We are Ready to Use It
Background  Certolizumab pegol is a pegylated humanised Fab’ fragment of a monoclonal antibody with high specificity for human TNF α  Phase II studies.
You Can Never Stop a Biologic
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
내과 R2 이지훈 N Engl J Med 2014;371:
William J. Sandborn, M.D., Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D., Stephen Hanauer, M.D., Jean-Frederic Colombel, M.D., Bruce E. Sands, M.D.,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Advances in the Treatment of Crohn’s Disease GASTROENTEROLOGY 2004;126:1574–1581.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Once-Daily Celecoxib Effective for Preventing Sporadic Colorectal Adenomas Slideset on: Arber N, Rácz I, Spicak J, et al. Chemoprevention of colorectal.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Multicenter, Placebo-Controlled Trial
Learning Objectives Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of inflammatory bowel disease. Summarize the latest.
Volume 137, Issue 4, Pages (October 2009)
The SPRINT Research Group
Early Surgery versus Conventional Treatment for Infective Endocarditis
HOPE: Heart Outcomes Prevention Evaluation study
The IDEAL Study Reference
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab  William J. Sandborn, Maria T. Abreu, Geert.
Abatacept for Crohn's Disease and Ulcerative Colitis
Volume 135, Issue 4, Pages (October 2008)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Volume 133, Issue 1, Pages (July 2007)
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease  Stephen B Hanauer, Carrie L Wagner,
Anti-integrin therapy in inflammatory bowel disease
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Volume 153, Issue 1, Pages e6 (July 2017)
Volume 384, Issue 9940, Pages (July 2014)
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Volume 130, Issue 2, Pages (February 2006)
Volume 147, Issue 3, Pages e3 (September 2014)
Volume 132, Issue 5, Pages (May 2007)
Volume 137, Issue 4, Pages (October 2009)
Volume 119, Issue 6, Pages (December 2000)
Adalimumab Induces Deep Remission in Patients With Crohn's Disease
William J. Sandborn, Stefan Schreiber, Brian G
Volume 119, Issue 6, Pages (December 2000)
Volume 154, Issue 6, Pages (May 2018)
Volume 132, Issue 1, Pages (January 2007)
Volume 135, Issue 5, Pages (November 2008)
Volume 384, Issue 9940, Pages (July 2014)
Original Article Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen Susan R. Davis, M.D., Ph.D., Michele Moreau, M.D., Robin Kroll,
Switch to RAL-containing regimen
Volume 121, Issue 5, Pages (November 2001)
Volume 126, Issue 2, Pages (February 2004)
Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.
Volume 142, Issue 5, Pages e2 (May 2012)
Volume 117, Issue 4, Pages (October 1999)
Volume 117, Issue 3, Pages (September 1999)
Volume 121, Issue 2, Pages (August 2001)
Slides compiled by Dr. Najma Ahmed
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months  Gary R. Lichtenstein, Ole Ø. Thomsen,
Presentation transcript:

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease William J. Sandborn, M.D., Christopher Gasink, M.D., Long-Long Gao, Ph.D., Marion A. Blank, Ph.D., Jewel Johanns, Ph.D., Cynthia Guzzo, M.D., Bruce E. Sands, M.D., Stephen B. Hanauer, M.D., Stephan Targan, M.D., Paul Rutgeerts, M.D., Ph.D., Subrata Ghosh, M.D., Willem J.S. de Villiers, M.D., Ph.D., Remo Panaccione, M.D., Gordon Greenberg, M.D., Stefan Schreiber, M.D., Simon Lichtiger, M.D.,and Brian G. Feagan, M.D., N Engl J Med 2012;367:1519-28 R2 Kyunghan Yoon / Prof. Changkyun Lee 

Background

BACKGROUND Refractory Crohn’s disease -> TNF antagonist 1/3 -> Do not have response to initial treatment (primary nonresponse) 1/3 -> Transient response or a switch to another therapy (secondary nonresponse). Interleukin- 12 and interleukin-23 Overexpression, polymorphism-> Pathogenesis of Crohn’s disease Ustekinumab : human IgG1κ monoclonal antibody, blocks the biologic activity of IL-12 & 23 Patients with moderate- to-severe Crohn’s disease that was resistant to TNF antagonists -> Effect of Ustekinumab ?? Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care (ADDITION-Europe)

Method

Methods Randomized, double-blind, placebo-controlled phase 2b trial of ustekinumab (Oct 2008 ~ Dec 2010) Primary end point Clinical response (≥100-p↓ from the baseline CDAI score) at week 6 Secondary end points Clinical remission (CDAI score, <150 points) at week 6 Clinical response at week 4, and clinical remission at week 22 among patients with a response to ustekinumab at week 6. Crohn’s Disease Activity Index (CDAI, 0~600) - Higher scores indicating worse disease - 50-point change indicating the minimal clinically important difference

1st randomization 2nd randomization

Methods Inclusion criteria 18 years old ↑ 3-month↑ history of Crohn’s disease with a score of 220 to 450 points on the CDAI Primary nonresponse, a secondary nonresponse, or unacceptable side effects after receiving a TNF antagonist No previous therapies specifically targeting interleukin-12 or interleukin-23 Exclusion criteria Bowel resection within 6 months before enrollment and those with the short-bowel syndrome Abscess, active tuberculosis, current infection, or other previous or current opportunistic infection or cancer.

Result

No significant difference Results Table 1. Baseline Characteristics of the Patients in the Induction Phase No significant difference

Ustekinumab > Placebo No significant difference Results Figure 1. Efficacy of Ustekinumab in the Induction Phase Response Ustekinumab > Placebo Remission No significant difference

Response & Remission (maintenance phase) Ustekinumab > Placebo Results Figure 2. Efficacy of Ustekinumab in the Maintenance Phase Response & Remission (maintenance phase) Ustekinumab > Placebo 69.4 41.7 42.5 27.4 P<0.001 P= 0.03

Results Serious infections Table 2. Adverse Events during the Induction Phase (Week 0 to Week 8) Serious infections Five patients receiving 6 mg/kg Ustekinumab(C. difficile infection, viral gastroenteritis, UTI, anal abscess, and vaginal abscess) One patient receiving 1 mg/kg of ustekinumab (staphylococcal infection in a central catheter) One patient receiving placebo (anal abscess) Serious adverse events & Infusion reactions were uncommon

Results Table 3. Adverse Events during the Maintenance Phase (Week 8 to Week 36) There were no deaths, major adverse cardiovascular events, tuberculosis, or other serious opportunistic infections One basal-cell carcinoma was reported in a patient who received 1 mg/kg of ustekinumab

Conclusion

Conclusions Induction therapy Maintenance therapy Remission?? Response & Remission↑ Response↑ Ustekunumab CD patients When compared with routine care, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was associated with small increases in the prescription of drugs and improvements in cardiovascular risk factors, but was not associated with signifi cant reductions in the incidence of cardiovascular events or death over 5 years. Placebo